A recent study published in JAMA Network Open explored the early neurodevelopmental outcomes of extremely preterm infants who received autologous cord blood therapy. While no significant differences were observed in brain imaging or neurodevelopment between the treated and untreated groups, the therapy showed promising results, with no infants assessed as high risk for cerebral palsy. The study suggests that autologous cord blood could offer potential neuroprotection, warranting further investigation in larger trials.
Industry Insights Fear, Trust and The Fragility of Cord Blood Banking
Cord blood can only be collected once, at birth. A recent AABB article explores how fear and reduced prenatal engagement, particularly in immigrant communities, are limiting cord blood donations. Fewer collections mean a less diverse inventory and fewer transplant options for patients in need. This article highlights the need to build trusted healthcare environments to support successful cord blood collection and long-term treatment options.
ViaCord in Focus - Advancing Newborn Health Through Science and Innovation
Life Sciences Review recently featured ViaCord’s continued leadership in cord blood and tissue banking, highlighting more than 30 years of experience supporting families. This feature explores how ViaCord is expanding beyond stem cell storage into newborn genetic services - offering families additional tools to better understand and plan for their future health needs.
Emerging Science Umbilical Cord MSCs Show Promise in Cartilage Regeneration
A review published in Stem Cells International highlights early research showing that stem cells from umbilical cord tissue may help repair damaged cartilage when injected into joints. In some studies, combining these cells with magnesium improved healing, leading to thicker cartilage, better attachment to the injury site, and stronger joint structure over time. More clinical research is needed to confirm long-term results.
Upcoming Event Sequencing Spotlight: How to Commence Newborn Genomic Research
Catch our upcoming webinar on newborn genomic sequencing, led by our colleagues at Revvity Omics. Learn how laboratories can implement whole genome sequencing programs and build the infrastructure needed to support genomic research in newborn health.
Trusted by families for 30 years and recognized by the following organizations and associations
ViaCord is proud to be a part of Revvity, a leading global healthcare company.
Disclaimer: Banking cord blood does not ensure that treatment will work, and only a doctor can determine when it can be used. This is intended for educational purposes only and should not be used or interpreted as information on treatments or diagnoses. Cord tissue stem cells have not been used in treatment yet. Research is ongoing. The content shall not be used to make a diagnosis or to replace or overrule a health care provider’s judgement. Always consult with a qualified and licensed physician or other medical care provider.
